Potential therapeutic interventions for fragile X syndrome
Josien Levenga1, Femke M S de Vrij, Ben A Oostra
1CBG-Department of Clinical Genetics, Erasmus MC, Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.
Trends in Molecular Medicine
|September 25, 2010
Summary
Fragile X syndrome (FXS) results from a lack of fragile X mental retardation protein (FMRP). Therapies targeting glutamate and GABA pathways show promise for treating FXS symptoms in models and patients.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Fragile X syndrome (FXS) is a genetic disorder caused by the absence of the fragile X mental retardation protein (FMRP).
- FMRP deficiency in neurons leads to intellectual disability, hyperactivity, and autistic-like behaviors.
- While gross brain malformations are absent, subtle abnormalities in neuronal spines are observed in FXS.
Purpose of the Study:
- To review targeted therapeutic strategies for Fragile X syndrome.
- To discuss the correction of disturbed excitatory (mGluR) and inhibitory (GABA) receptor pathways in FXS.
- To evaluate therapies tested in animal models and clinical trials for FXS.
Main Methods:
- Discussion of therapeutic strategies targeting metabotropic glutamate receptors (mGluRs).
- Review of interventions aimed at correcting gamma-aminobutyric acid (GABA) receptor pathway disturbances.
- Analysis of data from preclinical studies in animal models of FXS.
- Examination of results from clinical trials involving patients with FXS.
Main Results:
- Altered group I mGluR-dependent and independent synaptic plasticity are implicated in FXS.
- Targeted therapies aim to restore normal synaptic function by modulating mGluR and GABA pathways.
- Preclinical and clinical investigations are exploring the efficacy of these targeted strategies.
Conclusions:
- Modulating mGluR and GABA pathways represents a promising therapeutic avenue for FXS.
- Further research and clinical trials are essential to validate the effectiveness of these interventions.
- Restoring FMRP function or compensating for its absence is key to treating FXS.
More Related Videos
10:58TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism
Published on: December 28, 2010
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Related Concept Videos
01:19Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
01:26Modeling in Therapy
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:24Operant Conditioning Intervention
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
In operant conditioning, behaviors that are...
01:24Treatment Strategies for Psychological Disorders
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...